Next Article in Journal
Fluoxetine Induces Apoptosis through Extrinsic/Intrinsic Pathways and Inhibits ERK/NF-κB-Modulated Anti-Apoptotic and Invasive Potential in Hepatocellular Carcinoma Cells In Vitro
Next Article in Special Issue
The Cutting Edge: The Role of mTOR Signaling in Laminopathies
Previous Article in Journal
Protective Effect of Koumine, an Alkaloid from Gelsemium Sempervirens, on Injury Induced by H2O2 in IPEC-J2 Cells
Previous Article in Special Issue
Balancing mTOR Signaling and Autophagy in the Treatment of Parkinson’s Disease
Article Menu
Issue 3 (February-1) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2019, 20(3), 755;

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy

College of Life Science and Bioengineering, Beijing Jiaotong University, Beijing 100044, China
Author to whom correspondence should be addressed.
Received: 10 January 2019 / Revised: 28 January 2019 / Accepted: 1 February 2019 / Published: 11 February 2019
(This article belongs to the Special Issue mTOR in Human Diseases)
Full-Text   |   PDF [675 KB, uploaded 11 February 2019]   |  


The mammalian or mechanistic target of rapamycin (mTOR) pathway plays a crucial role in regulation of cell survival, metabolism, growth and protein synthesis in response to upstream signals in both normal physiological and pathological conditions, especially in cancer. Aberrant mTOR signaling resulting from genetic alterations from different levels of the signal cascade is commonly observed in various types of cancers. Upon hyperactivation, mTOR signaling promotes cell proliferation and metabolism that contribute to tumor initiation and progression. In addition, mTOR also negatively regulates autophagy via different ways. We discuss mTOR signaling and its key upstream and downstream factors, the specific genetic changes in the mTOR pathway and the inhibitors of mTOR applied as therapeutic strategies in eight solid tumors. Although monotherapy and combination therapy with mTOR inhibitors have been extensively applied in preclinical and clinical trials in various cancer types, innovative therapies with better efficacy and less drug resistance are still in great need, and new biomarkers and deep sequencing technologies will facilitate these mTOR targeting drugs benefit the cancer patients in personalized therapy. View Full-Text
Keywords: mTOR; PI3K; cancer; inhibitor; therapy mTOR; PI3K; cancer; inhibitor; therapy

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Tian, T.; Li, X.; Zhang, J. mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy. Int. J. Mol. Sci. 2019, 20, 755.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top